Microbot Medical Inc. — fact timeline

Microbot Medical Inc. issued 66,224 preferred investment options of warrant to H.C. Wainwright & Co., LLC.

“The Company issued the New PIOs, and 66,224 preferred investment options (the “Wainwright PIOs”) to H.C. Wainwright & Co., LLC (“Wainwright”) pursuant to the Company’s May 29, 2024 engagement letter with Wainwright, as amended, pursuant to the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), available under Section 4(a)(2) thereof.”

Microbot Medical Inc. issued 1,324,488 new series J preferred investment options of warrant to the Holder.

“On October 6, 2025, the holder (the “Holder”) of 1,324,488 series H preferred investment options (the “Existing POIs”) of Microbot Medical Inc., a Delaware corporation (the “Company”), pursuant to that previously-disclosed inducement agreement with the Company dated September 14, 2025 (the “Letter Agreement”), exercised the Existing PIOs for 1,324,488 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at an exercise price of $2.10 per share, and the Holder received 1,324,488 new series J preferred investment options pursuant to the terms of the Letter Agreement (the “New PIOs”).”

Microbot Medical Inc. issued 1,324,488 shares of the Company’s common stock of preferred stock to the Holder for exercise price of $2.10 per share.

“On October 6, 2025, the holder (the “Holder”) of 1,324,488 series H preferred investment options (the “Existing POIs”) of Microbot Medical Inc., a Delaware corporation (the “Company”), pursuant to that previously-disclosed inducement agreement with the Company dated September 14, 2025 (the “Letter Agreement”), exercised the Existing PIOs for 1,324,488 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at an exercise price of $2.10 per share, and the Holder received 1,324,488 new series J preferred investment options pursuant to the terms of the Letter Agreement (the “New PIOs”).”

Microbot Medical Inc. issued 374,167 shares of Common Stock of common stock for between $1.875 and $2.6625 per share.

“the exercise of a like number of preferred investment options (the “PA Options”) by the holder of such PA Options. The exercise prices per share of the PA Options was between $1.875 and $2.6625, generating gross proceeds to the Company, before deducting placement agent fees and expenses, of approximately $896,000. The shares issued upon exercise of the PA”

Microbot Medical Inc. issued 30,000 preferred investment options of warrant to H.C. Wainwright & Co., LLC.

“The Company issued the New PIOs, and 30,000 preferred investment options (the “Wainwright PIOs”) to H.C. Wainwright & Co., LLC (“Wainwright”)”

Microbot Medical Inc. issued 225,000 shares of Common Stock of common stock to holders of Series H preferred investment options for exercise price per share of $2.10, generating gross proceeds of $472,500.

“On September 8, 2025, the Company issued 225,000 shares of Common Stock upon the exercise of a like number of Series H preferred investment options (the “Series H Options”) by the holders of such options. The exercise price per share of the Series H options was $2.10, generating gross proceeds to the Company, before deducting placement agent fees and expenses, of $472,500”

Microbot Medical Inc. issued preferred investment options to purchase an aggregate of (i) 10,362 shares of Common Stock at an exercise price of $1.875 (ii) 31,429 shares of Common Stock at of warrant to H.C. Wainwright & Co., LLC for cash fee equal to 7.0% of the gross proceeds received by the Company from the Offerings, plus a management fee equal to 1.0% of the gross proceeds.

“shares of the Common Stock issuable upon exercise of the Existing PIOs are registered pursuant to the post-effective amendments on Form S-3 to registration statements on Form S-1 (File Nos. 333-280113 and 333-284688) and the registration statement on Form S-3 (File No. 333-285690), declared effective by the SEC on July 3, 2024, April 2, 2025 and April 1,”

Microbot Medical Inc. issued to purchase up to an aggregate of 13,989,115 shares of Common Stock of warrant to certain holders (the Holders) of existing series F, G, H and I preferred investment options for exercise of Existing PIOs at exercise prices ranging from $1.50 to $2.13 per share.

“the Holder exercised for cash its Existing PIOs to purchase an aggregate of 13,989,115 shares of Common Stock, at exercise prices ranging from $1.50 to $2.13 per share, in consideration for the Company’s agreement to issue new series J preferred investment options (the “New PIOs”) to purchase up to an aggregate of 13,989,115 shares of Common Stock (the “New PIO Shares”) at an exercise price of $4.50 per share”

Microbot Medical Inc.: Increased authorized common stock from 61,000,000 to 120,000,000 shares, and total authorized shares from 61,000,000 to 121,000,000 shares (effective 2025-06-10).

“On June 10, 2025 (the “Effective Time”), in keeping with stockholder approval obtained at the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of Microbot Medical Inc. (the “Company”), discussed further below in this Current Report on Form 8-K, the Company filed with the State of Delaware a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended, which increased the total number of shares of common stock, par value $0.01 per share (the “Common Stock”) authorized for issuance to 120,000,000 shares, with a corresponding increase in the total authorized shares from 61,000,000 to 121,000,000.”

Microbot Medical Inc.: Reduced stockholder meeting quorum requirement from majority to one-third of votes entitled to be cast (effective 2025-04-14).

“On April 14, 2025, the Board of Directors of Microbot Medical Inc. (the “Company”) approved an amendment to the Company’s amended and restated by-laws, as amended (the “By-laws”), effective immediately, to reduce the quorum requirement for a meeting of stockholders from a majority of the votes entitled to be cast on the matter to one third of the votes entitled to be cast on the matter.”

Microbot Medical Inc. entered into Settlement Agreement and Release with Empery Asset Master Ltd., Empery Tax Efficient, LP, Empery Tax Efficient III, LP and Hudson Bay Master Fund Ltd. valued at $2,154,000 (effective 2024-01-26).

“As of January 26, 2024 (the “Effective Date”), Microbot Medical Inc. (the “Company”) entered into a Settlement Agreement and Release (the “Settlement Agreement”) with Empery Asset Master Ltd., Empery Tax Efficient, LP, Empery Tax Efficient III, LP and Hudson Bay Master Fund Ltd. (collectively, “Plaintiffs”), which resolved and settled the below referenced litigation between the Company and Plaintiffs.”

Microbot Medical Inc. entered into Inducement Letter with certain holders valued at approximately $2.73 million (effective 2023-12-29).

“On December 29, 2023, Microbot Medical Inc., a Delaware corporation (the “Company”), entered into a preferred investment option exercise inducement offer letter (the “Inducement Letter”) with certain holders (the “Holders”)”

Dr. Juan Diaz-Cartelle was appointed as Chief Medical Officer at Microbot Medical Inc..

“On November 21, 2023, Microbot Medical Inc. (the “Company”) announced the appointment of Dr. Juan Diaz-Cartelle, age 48, as the Company’s new Chief Medical Officer (“CMO”).”

Microbot Medical Inc. shareholders approved Ratification of Brightman Almagor Zohar & Co. as independent auditor for 2023 at the 2023-11-02 meeting.

“Proposal 5: The ratification of Brightman Almagor Zohar & Co., a Member of Deloitte Touche Tohmatsu Limited, or its U.S. affiliate, as the Company’s independent registered public accounting firm for the year ending December 31, 2023: Number of Votes Cast in Favor Number of Votes Cast Against Number of Votes Abstained Broker Non-Votes 6,100,498 74,658 261,965 0”

Microbot Medical Inc. shareholders approved Advisory resolution regarding frequency of future say-on-pay votes at the 2023-11-02 meeting.

“Proposal 4: The approval of a non-binding advisory resolution regarding the frequency of future non-binding advisory votes related to named executive officer compensation: One Year Two Years Three Years Number of Votes Abstained Broker Non-Votes 2,201,561 86,486 1,383,749 135,677 2,629,648”

Microbot Medical Inc. shareholders approved Advisory resolution supporting compensation of named executive officers at the 2023-11-02 meeting.

“Proposal 3: The approval of a non-binding advisory resolution supporting the compensation of the Company’s named executive officers: Number of Votes Cast in Favor Number of Votes Cast Against Number of Votes Abstained Broker Non-Votes 2,197,751 1,547,396 62,326 2,629,648”

Microbot Medical Inc. shareholders approved Approval of amendment to 2020 Omnibus Performance Award Plan to increase authorized shares by 600,000 at the 2023-11-02 meeting.

“Proposal 2: The approval of an amendment to the Company’s 2020 Omnibus Performance Award Plan, to increase the number of authorized shares of common stock reserved for issuance by 600,000, from 1,420,652 to 2,020,652: Number of Votes Cast in Favor Number of Votes Cast Against Number of Votes Abstained Broker Non-Votes 2,193,713 1,563,087 50,673 2,629,648”

Microbot Medical Inc. shareholders approved Election of two nominees to serve as Class II Directors until the 2026 Annual Meeting at the 2023-11-02 meeting.

“Proposal 1: Election of the two nominees listed below to serve as Class II Directors on the Board of Directors of the Company until the 2026 Annual Meeting of Shareholders and until their respective successors have been duly elected and qualified: Name Number of Votes Cast in Favor Number of Votes Withheld Broker Non-Votes Scott Burell 3,151,413 656,060 2,629,648 Aileen Stockburger 3,287,071 520,402 2,629,648”

Eyal Morag resigned as Chief Medical Officer at Microbot Medical Inc..

“On August 29, 2023, Eyal Morag, the Company’s Chief Medical Officer, resigned from his position with the Company, effective November 29, 2023.”

Microbot Medical Inc. entered into Securities Purchase Agreements with institutional investors valued at aggregate gross proceeds from the Offerings ... of approximately $2.0 million (effective 2023-06-26).

“On June 26, 2023, Microbot Medical Inc., a Delaware corporation (the “Company”), entered into Securities Purchase Agreements (the “Purchase Agreements”) with institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market (the “Registered Offering”), an aggregate of 624,618 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”), at an offering price of $3.25 per share, for aggregate gross proceeds from the Offerings (as defined below) of approximately $2.0 million before deducting the placement agent fee (as described in greater detail below) and related offering expenses.”

Microbot Medical Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC (effective 2023-05-16).

“On May 16, 2023 and in connection with the Offerings, the Company entered into an engagement letter (the “Engagement Letter”) with H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which Wainwright agreed to serve as the exclusive placement agent for the issuance and sale of securities of the Company pursuant to the Purchase Agreement.”

Microbot Medical Inc. entered into Purchase Agreements with institutional investors valued at approximately $1.5 million (effective 2023-06-02).

“On June 2, 2023, Microbot Medical Inc., a Delaware corporation (the “Company”), entered into Securities Purchase Agreements (the “Purchase Agreements”) with institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market (the “Registered Offering”), an aggregate of 701,756 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”), at an offering price of $2.1375 per share, for aggregate gross proceeds from the Offerings (as defined below) of approximately $1.5 million before deducting the placement agent fee (as described in greater detail below) and related offering expenses.”

Microbot Medical Inc. amended Warrant Amendment Agreement with the Investor.

“In connection with the Offering, the Company also entered into a warrant amendment agreement (the “Warrant Amendment Agreement”) with the Investor.”

Microbot Medical Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC (effective 2023-05-16).

“On May 16, 2023 and in connection with the Offering, the Company entered into an engagement letter (the “Engagement Letter”) with H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which Wainwright agreed to serve as the exclusive placement agent for the issuance and sale of securities of the Company pursuant to the Purchase Agreement.”

Microbot Medical Inc. entered into Purchase Agreement with an institutional investor valued at approximately $2.66 million (effective 2023-05-23).

“On May 23, 2023, Microbot Medical Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor (the “Investor”), pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market (the “Offering”), (i) an aggregate of 975,000 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”), at an offering price of $2.20 per share and (ii) pre-funded warrants exercisable for up to 234,500 shares of Common Stock (the “Pre-Funded Warrants”) to the Investor at an offering price of $2.1999 per Pre-Funded Warrant, for aggregate gross proceeds from the Offering of approximately $2.66 million”

Microbot Medical Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC valued at an aggregate cash fee equal to 7.0% of the gross proceeds (effective 2023-05-16).

“On May 16, 2023 and in connection with the Offering, the Company entered into an engagement letter (the “Engagement Letter”) with H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which Wainwright agreed to serve as the exclusive placement agent for the issuance and sale of securities of the Company pursuant to the Purchase Agreement.”

Microbot Medical Inc. entered into Securities Purchase Agreement with an institutional investor valued at aggregate gross proceeds from the Offering of approximately $1.4 million (effective 2023-05-22).

“On May 22, 2023, Microbot Medical Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor (the “Investor”), pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market (the “Offering”), an aggregate of 655,569 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”), at an offering price of $2.20 per share, for aggregate gross proceeds from the Offering of approximately $1.4 million before deducting the placement agent fee (as described in greater detail below) and related offering expenses.”

Rachel Vaknin was appointed as Chief Financial Officer at Microbot Medical Inc..

“As of April 1, 2022, the Company appointed Rachel Vaknin, age 43, as its Chief Financial Officer.”

David Ben Naim resigned as Chief Financial Officer at Microbot Medical Inc..

“As of April 1, 2022, David Ben Naim, the Chief Financial Officer of Microbot Medical Inc. (the “Company”), resigned from his position with the Company, effective immediately.”